Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 0.66 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.66 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.66 |
| ▸ | KDM1A | O60341 | 2/20 | 0.64 |
| ▸ | METAP2 | P50579 | 1/20 | 0.61 |
| ▸ | GPR27 | Q9NS67 | 8/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.50 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7627121 | 0.94 | SLC10A6 (0.71) | SLC10A6SLC10A2SLC10A1KDM1AMETAP2 | |
| SCHEMBL23200349 | 0.85 | KDM4E (0.63) | SLC10A6SLC10A2SLC10A1GPR27AVPR2 | |
| SCHEMBL7213164 | 0.85 | SLC10A6 (0.71) | SLC10A6SLC10A2SLC10A1KDM1AMETAP2 | |
| SCHEMBL7116008 | 0.84 | SLC10A6 (0.85) | SLC10A6SLC10A2SLC10A1KDM1AMETAP2 | |
| SCHEMBL7128725 | 0.82 | SLC20A2 (0.66) | SLC10A6SLC10A2SLC10A1KDM1AGPR27 | |
| SCHEMBL6756862 | 0.80 | SLC10A6 (1.00) | SLC10A6SLC10A2SLC10A1METAP2GPR27 | |
| SCHEMBL7126120 | 0.79 | SLC10A6 (0.98) | SLC10A6SLC10A2SLC10A1METAP2GPR27 | |
| SCHEMBL7208184 | 0.79 | SLC10A6 (0.76) | SLC10A6SLC10A2SLC10A1KDM1AMETAP2 | |
| SCHEMBL23200293 | 0.79 | KDM4E (0.67) | SLC10A6SLC10A2SLC10A1METAP2GPR27 | |
| SCHEMBL5117189 | 0.79 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1KDM1AMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | claimed |
| US-20190077772-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2019-03-14 | — | — | US | claimed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | DUKE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | DUKE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-10562864-B2 | Chemical modulators of immune checkpoints and therapeutic use | DUKE UNIVERSITY (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562864-B2 | Chemical modulators of immune checkpoints and therapeutic use | DUKE UNIVERSITY (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-20190077772-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| US-20190077772-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| US-10189797-B2 | Chemical modulators of immune checkpoints and therapeutic use | DUKE UNIVERSITY (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20170190675-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-20170190675-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-20170190675-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562864-B2 | Chemical modulators of immune checkpoints and therapeutic use | CD274, PDCD1, PDCD1LG2 | SLC10A6 4475/4885SLC10A2 4394/4885SLC10A1 3759/4885 |
| US-10189797-B2 | Chemical modulators of immune checkpoints and therapeutic use | CD274, PDCD1, PDCD1LG2 | SLC10A6 4475/4885SLC10A2 4394/4885SLC10A1 3759/4885 |
| US-20190077772-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | CD274, PDCD1, PDCD1LG2 | SLC10A6 4475/4885SLC10A2 4394/4885SLC10A1 3759/4885 |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | SLC10A6 1693/4885SLC10A2 259/4885SLC10A1 55/4885 |
| US-20170190675-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | CD274, PDCD1, PDCD1LG2 | SLC10A6 4475/4885SLC10A2 4394/4885SLC10A1 3759/4885 |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | SFRP1, FZD7, WNT1 | SLC10A6 1693/4885SLC10A2 259/4885SLC10A1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.